drp 1

Drp1-IN-1 (comp A-7) is a Drp1 protein inhibitor with an IC50 value of 0.91 μM.

DRP1i27, a potent human dynamin-related protein 1 (Drp1) inhibitor, targets the GTPase site of Drp1, forming hydrogen bonds with Gln34 and Asp218. It mitigates Drp1-mediated mitochondrial fission in cell line models and offers protection against simulated ischemia-reperfusion injury.

P110 TFA is a dynamin-related protein 1 (Drp1) inhibitor, inhibits Drp1 GTPase activity.

Compound P110 (Drp1 peptide inhibitor P110) is a selective Drp1 peptide inhibitor with neuroprotective effects. It inhibits the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and alleviates dopamine neuron loss, dopaminergic terminal damage, and behavioral deficits caused by MPTP. This compound is useful for Alzheimer's disease research. Additionally, Compound P110 reduces mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemia, and myocardial infarction.

Sirpiglenastat (DRP-104), a glutamine antagonist and prodrug of DON, exhibits antitumor activity by inhibiting glutamine metabolism and stimulating both the innate and adaptive immune systems.